[1] |
刘晓亮. Noonan综合征的诊治进展[J]. 临床儿科杂志, 2016, 34(1): 64-67.
|
[2] |
Roberts AE, Allanson JE, Tartaglia M, et al. Noonan syndrome[J]. Lancet, 2013, 381(9863): 333-342.
doi: 10.1016/S0140-6736(12)61023-X
pmid: 23312968
|
[3] |
刘霞, 苏喆. Noonan综合征的诊断治疗进展[J]. 中华实用儿科临床杂志, 2014, 29(20): 1531-1533.
|
[4] |
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2020, 76(25): 3022-3055.
doi: 10.1016/j.jacc.2020.08.044
|
[5] |
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. J Am Soc Echocardiogr, 2015, 28(1): 1-39. e14.
doi: 10.1016/j.echo.2014.10.003
|
[6] |
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424.
doi: 10.1038/gim.2015.30
pmid: 25741868
|
[7] |
罗光月, 陆韦. Noonan综合征发病机制的研究进展[J]. 疑难病杂志, 2021, 20(10): 1077-1080.
|
[8] |
Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines[J]. Pediatrics, 2010, 126(4): 746-759.
doi: 10.1542/peds.2009-3207
pmid: 20876176
|
[9] |
Wu X, Yin J, Simpson J, et al. Increased BRAF heterodimerization is the common pathogenic mechanism for Noonan syndrome-associated RAF1 mutants[J]. Mol Cell Biol, 2012, 32(19): 3872-3890.
doi: 10.1128/MCB.00751-12
|
[10] |
李辛, 王秀敏, 王剑, 等. Noonan综合征的临床实践指南[J]. 中华医学遗传学杂志, 2020, 37(3): 324-328.
|
[11] |
Lioncino M, Monda E, Verrillo F, et al. Hypertrophic cardiomyopathy in RASopathies: diagnosis, clinical characteristics, prognostic implications, and management[J]. Heart Fail Clin, 2021, 18(1): 19-29.
doi: 10.1016/j.hfc.2021.07.004
|
[12] |
Pierpont ME, Digilio MC. Cardiovascular disease in Noonan syndrome[J]. Curr Opin Pediatr, 2018, 30(5): 601-608.
doi: 10.1097/MOP.0000000000000669
pmid: 30024444
|
[13] |
James D, April M, Bonnie A, et al. Outcomes in chlidren with Noonan syndrome and hypertrophic cardiomyopathy: a study from the pediatric cardiomyopathy registry[J]. Am Heart J, 2012, 164(3): 442-448.
doi: 10.1016/j.ahj.2012.04.018
|
[14] |
Prendiville TW, Gauvreau K, Tworog-Dube E, et al. Cardiovascular disease in Noonan syndrome[J]. Arch Dis Child, 2014, 99(7): 629-634.
pmid: 24534818
|
[15] |
Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders[J]. Best Pract Res Clin Endocrinol Metab, 2011, 25(1): 161-179.
doi: 10.1016/j.beem.2010.09.002
pmid: 21396583
|
[16] |
Tafazoli A, Eshraghi P, Koleti ZK, et al. Noonan syndrome - a new survey[J]. Arch Med Sci, 2017, 13(1): 215-222.
doi: 10.5114/aoms.2017.64720
pmid: 28144274
|
[17] |
Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis[J]. Mol Syndromol, 2010, 1(1): 2-26.
doi: 10.1159/000276766
pmid: 20648242
|